In-vitro Comparison of Cytotoxicity of Two Bioactive Glasses in Micropowder and Nanopowder forms

Mansour Rismanchian\textsuperscript{a}, Niloufar Khodaeian\textsuperscript{b}, Lida Bahramian\textsuperscript{a}, Mohammadhosein Fathi\textsuperscript{c} and Hojjat Sadeghi-Aliabadi\textsuperscript{d}\textsuperscript{*}

\textsuperscript{a}Dental Implant Research Center, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran. \textsuperscript{b}Dental Materials Research Center and Prosthodontics, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran. \textsuperscript{c}Biomaterials Research Group, Department of Materials Engineering, Isfahan University of Technology, Isfahan, Iran. \textsuperscript{d}Department of Medicinal Chemistry, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

The cytotoxicity of the biomaterials is a key issue that should be addressed prior to pre-clinical applications. This study was designed to evaluate and compare the cytotoxicity of two forms of bioactive glasses: nanopowder and micropowder. Human HGF1-P153 gingival fibroblast cells were used to evaluate the cytotoxicity of 0.5, 1, 1.5, 2, 5, 10, 15 and 20 mg/mL concentrations of the two bioactive glasses via MTT assay. The results were statistically analyzed using analysis of variance and Tukey’s test. A p-value less than 0.05 was considered statistically significant. Results showed that two bioactive glasses had statistically significant differences at 5, 10, 15 and 20 mg/mL concentrations (p-value < 0.05) and there was no correlation between time and cell cytotoxicity of bioactive glasses (p-value > 0.05), using t-test and Spearman’s correlation coefficient. We conclude that that cytotoxicity of nanopowder bioactive glass at concentrations ≤ 2 mg/mL was similar to micropowder bioactive glass at 24 and 48 h, however, it is more cytotoxic at concentrations ≥ 5 mg/mL in the first 48 h of applications.

Keywords: Micropowder; Nanopowder; MTT assay; HGF1-P153 cell line.

Introduction

The concept of bioactive glass (bioglass) was developed and examined for the first time by Hench at the beginning of the 70s (1, 2). Bioactive glass is a bone substitute material that is thought not only to have osteoconductivity, but is also responsible for osteoproduction by stimulating proliferation and differentiation of osteoprogenitor cells through a direct genetic control (1,3-5). The discovery of this new material led Hench and Wilson to propose the concept of “osteostimulation” or “osteopromotion” to define this class of bioactive material and its effect on the genetic activation of bone cells (6). Bioactive glass is a surface reactive material that, when in contact with physiological fluids, releases soluble ionic products and induces insulin-like growth factor II mRNA expression and protein synthesis that have been suggested to stimulate in-vitro osteogenesis (4, 7). In addition in-vivo studies have demonstrated beneficial results from their use in various clinical situations.
(8-11). They are now clinically approved for use in dense form in non-load bearing applications such as middle ear prosthesis and endosseous ridge implants and as a particulate for periodontal defect repair (12-13). They have potentials as bone replacement graft materials and have effectiveness as an adjunct to intrabony defects surgical treatment (12-14). Recent investigations have suggested that bioactive glasses have a much better performance in bone tissue engineering than hydroxyapatite (HA) (4, 15-17). After implantation, interaction with surrounding tissues results in a time-dependent alteration of the materials’ surface and the formation of a hydroxyl carbonate apatite layer that is very similar to the mineral phase of bone (2). Results of in-vivo implantation show that these compositions produce no local or systemic toxicity, no inflammation and no foreign-body response and possess antimicrobial properties (18, 19).

It seems that nanostructure bioceramic has better bioactivity compared to coarser crystals (20, 21). By controlling the structure and particle size in the range of nanoscale, some properties of bioactive glass such as osteoconductivity, sintering characters, solubility and mechanical reliability can be improved (22). The biocompatibility and cytotoxicity of the novel biomaterials is a key issue that should be addressed prior to pre-clinical applications. Thus, the aim of this study was to evaluate and compare the cytotoxicity of a nanopowder bioactive glass with a micropowder bioactive glass named NovaBone® as trade mark. The null hypothesis was that nanopowder bioactive glass will show an acceptable biocompatibility when compared to micropowder bioactive glass.

Experimental

Cells

Human HGF3-PI53 gingival fibroblast was obtained from the Pasteur Institute of Iran (Tehran). Cells were cultured in Roswell Park Memorial Institute (RPMI 1640, Sigma, USA) medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin antibiotic solution (10000 Unit/mL penicillin and 10 mg/mL streptomycin). Cells were incubated at 37°C with 5% CO₂ and 95% humidity as reported previously (23-25).

Preparation of different bioglass concentrations

Micropowder bioactive glass (NovaBone®) as an FDA approved bone graft was purchased from US Biomaterials Corporation (Alachua, USA) with a particle size range of 90-710 µm containing 35.42 mol% SiO₂, 57.44 mol% CaO and 7.15 mol% P₂O₅. A sol-gel derived nanopowder bioactive glass, with particle size mainly below 100 nanometers and containing 62.17 mol% SiO₂, 28.47 mol% CaO and 9.25 mol% P₂O₅ were produced in Isfahan University of Technology (26, 27). Each bioactive glass was brought into suspensions with 0.5, 1, 1.5, 2, 5, 10, 15 and 20 mg/mL of medium. For achieving equilibration, these suspensions were placed into a shaker incubator for 48 h and afterwards were centrifuged for 10 min with 4000 rpm and the upper liquid was extracted. In order to sterilize the extract, it was filtered through a 0.2 µm microbiological filter.

Cell viability assay

Human gingival fibroblast cells were seeded (2×10⁴ cells per well) in a 96-well plate and allowed to grow. After 24 h, different concentrations of bioactive glasses were added to the cells. The culture without extract was used as a negative control. Each condition was set up in triplicate. Plates were assayed 24 and 48 h after the addition of extracts. The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay was used in this study to measure cell vitality and proliferation. The MTT agent reacts with its tetrazolium ring to produce blue formazan crystals in viable cells. At 24 and 48 h, the supernatant was removed from the wells, and the cells were rinsed three times with phosphate-buffered saline (PBS) to eliminate nonviable cells. 150 µL of fresh media was added to each well and then twenty micro liters per well of the MTT solution (5 mg/mL in PBS) was added, and the cells were incubated at 37°C for 4 h to allow the formation of formazan crystal. After incubation, the supernatant was removed, and 150 µL dimethyl sulfoxide was then added to each well to dissolve the formazan.
Crystals under continuous pipetting. The optical density was read spectrophotometrically at a wavelength of 540 nm using microplate reader (Awareness, USA) and the percentage of living cells was calculated using the following formula:

\[
\text{%Cell survival} = \frac{\text{Sample absorbance} - \text{blank absorbance}}{\text{control absorbance} - \text{blank absorbance}} \times 100
\]

Where blank absorbance was the media alone and the control absorbance was the cells with media alone. Cells without extracts were used as the reference for 100% cell survival. The results from three individual experiments were averaged and statistically analyzed using t-test and Spearman’s correlation coefficient. A p-value less than 0.05 was considered statistically significant.

Results

To detect changes in mitochondrial viability for gingival fibroblast cells incubated with different concentrations of two bioactive glasses tested, we measured the percentage of viable cells after 24 and 48 h using MTT assay (Figures 1 and 2). Statistically significant differences in cytotoxicity was found between the two bioactive glasses after 24 and 48 h. Two bioactive glasses had statistically significant differences only in 5, 10, 15 and 20 mg/mL concentrations (p-value < 0.05). Spearman’s correlation coefficient between concentration and cell cytotoxicity of micropowder and nanopowder bioglass were 0.941 and 0.951, respectively and there was a strong correlation between concentration and cytotoxicity in each group. As seen in Figures 3 and 4 there was no correlation between time and cell toxicity of the two bioactive glasses (p-value = 0.923 and 0.939 for micropowder and nanopowder bioglass, respectively using student t-test).

Discussion

The null hypothesis was accepted only for the concentration ≤ 2 mg/mL. Bioactive glass is a non-resorbable biomaterial and its medical use evolved three decades ago for its reported advantages of forming a strong bond with living tissues. Different concentrations of bioactive glass can be used in clinical applications. For example, a composition with 1.67 g/mL used for the treatment of hypersensitive teeth and even higher concentrations were used in the experiments by Allan et al. (28, 29). The biomaterials on the nano scale could stimulate reactions between the materials and the cells. For example, enhanced adhesion of osteoblasts
has been observed on nanophase alumina, titanium and HA when compared to conventional bioceramics (30, 31). The use of nanopowder bioactive glass may increase particle solubility and enhance the release of such ions as calcium, phosphate and silica, thereby increasing pH level (26). Thus, the antimicrobial effects of bioactive glasses could be greatly enhanced by lowering their particle size, leading to their immediate release of alkaline species (32). Another advantage of reducing the particle size is higher resorption rate. Bioactive gel-glasses with higher silica contents had a slower rate of resorption, hence the resorption rate of bioactive glasses with high silica contents should be enhanced by reducing the particle size through a greater surface area of nanoparticles in contact with physiological fluids (26). Silicone is involved in the early stages of bone calcification, thus, the nanopowder bioglass may be able to provide suitable conditions for the differentiation of osteoprogenitor cells to osteoblasts by releasing proper amounts of silica in their surrounding in-vivo environment.

In this study, the in-vitro biocompatibility of two bioactive glasses was investigated via MTT assay. Data are expressed as the percentage of inhibition compared with negative control in which cell survival was assumed 100 % (mean ± SD, n = 9).

Figure 2. Viability of human HGF3-PI53 gingival fibroblasts exposed to different concentrations of Novabone and nanopowder bioactive glass after 48 h incubation. The cytotoxicity was determined by MTT assay. Data are expressed as the percentage of inhibition compared with negative control in which cell survival was assumed 100 % (mean ± SD, n = 9).

Figure 3. Viability of human HGF3-PI53 gingival fibroblasts exposed to different concentrations of Novabone bioactive glass after 24 and 48 h incubation. The cytotoxicity was determined by MTT assay. Data are expressed as the percentage of inhibition compared with negative control in which cell survival was assumed 100 % (mean ± SD, n = 9).
assay. The results revealed that the presence of nanopowder bioactive glass at concentration of 0.5, 1, 1.5 and 2 mg/mL did not affect viability of fibroblast cells, when compared with micropowder bioactive glass, but at higher concentrations, significantly less viability of cells was observed in nanopowder bioactive glass.

Doostmohammadi et al. used MTT assay to evaluate the cytotoxicity of 63S bioactive glass at concentrations of 5, 50, 100, 200 µg/mL on stem cells after 24, 72 and 96 h. They found that during the first day, cell proliferation was observed only in the culture under particle-free medium. Then, an increasing trend of cell number was measured during time in all cultures. After 72 h, cells cultured in particle-free medium showed the highest viability compared to that in other groups. However, after 96 h, there were no significant differences between the viability in the groups. They suggested that the initial inhibition of cell proliferation may be due to the adaptation of cells to the new growth medium (23). Mortazavi et al. evaluated the cytotoxicity of synthesized 58S, 63S and 72S nanopowders bioactive glasses using the sol-gel technique at concentrations of 6.25, 12.5, 25, 50 and 100 mg/mL on mouse fibroblast cells. The results showed that although 58S had some cytotoxic effects at 24 and 48 h incubation, it gave more viability and proliferation by 72 h than the control. After 24 and 48 h, 63S and 72S showed no statistically significant differences with control group (26).

Smaller particle size results in the higher resorption rate and particle solubility. This may be responsible of more cytotoxicity in the first 48 h of application of nanopowders bioactive glasses compared with micropowders at the concentrations of more than 2 mg/mL in our study. These findings were not in agreement with Mortazavi et al. study which showed that 63S nanopowder bioactive glass at the concentrations of more than 6.25 mg/mL did not affect the viability of mouse fibroblast after 24 and 48 h (26). Their study was conducted on mouse fibroblasts and this may have contributed to the different results; thus more studies are needed to compare the reaction of different cells to bioactive glass. There was no correlation between time and cell toxicity of two bioactive glasses assessed in this study. The results were not in agreement with Doostmohammadi et al. study (23). Although they used bioactive glasses in concentrations much less than our studies, cells may adapt more easily to the growth medium at lower concentrations.

The important point to be considered for the comparison of two bioglasses is the difference in their particle sizes. Compared to the microparticles, nanoparticles have about 1000 times more surface area and thus the amount and rate of ion release from nanoparticles are extremely higher. In other words, the bioactivity of nanoparticles is higher in comparison with...
the same mass of microparticles. Genotoxicity of nano and micro bioactive glasses at the concentrations higher than 4 mg/mL has been evaluated in Tavakoli et al. study. They revealed that nanopowder glasses were more active in biological systems (33).

Conclusion

Based on the findings of this study, it can be concluded that cytotoxicity of nanopowder bioactive glass at concentrations \( \leq 2 \text{ mg/mL} \) is similar to micropowder bioactive glass at 24 and 48 h, however, it is more cytotoxic at concentrations \( \geq 5 \text{ mg/mL} \) in the first 48 h of application.

Acknowledgments

This study was supported by Isfahan University of Medical Sciences Grant #388585. The authors would like to thank Torabinejad Dental Research Center and cell culture laboratory staff for their kind support.

Conflict of Interest

We certify that there is no conflict of interest with any financial organization or trading companies regarding the material discussed in the manuscript.

References

(1) Hench LL, Splinter RJ, Allen WC and Greenlee TK. Bonding mechanism at the interface of ceramic prosthetic materials. J. Biomed. Mater. Res. (1971) 5: 117-141.
(2) Hench LL and Paschall HA. Direct chemical bond of bioactive glass-ceramic materials to bone and muscle. J. Biomed. Mater. Res. (1973) 7: 25-42.
(3) Hench LL and Polak JM. Third-generation biomedical materials. Science. (2002) 295: 1014-1017.
(4) Xynos ID, Edgar AJ, Buttery LD, Hench LL and Polak JM. Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis. Biochem. Biophys. Res. Commun. (2000) 276: 461-465.
(5) Hench LL. Genetic design of bioactive glass. J. Eur. Ceram. Soc. (2009) 29: 1257-65.
(6) Hench LL and Wilson J. Surface-active biomaterials. Science. (1984) 226: 630-636.
(7) Tsigkou O, Jones JR, Polak JM and Stevens MM. Differentiation of fetal osteoblasts and formation of mineralized bone nodules by 45S5 Bioglass conditioned medium in the absence of osteogenic supplements. Biomaterials. (2009) 30: 3542-3550.
(8) Froum S, Cho SC, Rosenberg E, Rohrer M and Tarnow D. Histological comparison of healing extraction sockets implanted with bioactive glass or demineralized freeze-dried bone allograft: a pilot study. J. Periodontal. (2002) 73: 94-102.
(9) Froum SJ, Weinberg MA and Tarnow D. Comparison of bioactive glass synthetic bone graft particles and open debridement in the treatment of human periodontal defects. A clinical study. J. Periodontal. (1998) 69: 698-709.
(10) Anderegg CR, Alexander DC and Freidman M. A bioactive glass particulate in the treatment of molar furcation invasions. J. Periodontal. (1999) 70: 384-387.
(11) Peltola M, Aitasalo K, Suonpää J, Varpula M and Yli-Urpo A. Bioactive glass S53P4 in frontal sinus obliteration: a long-term clinical experience. Head. Neck. (2006) 28: 834-841.
(12) Shapoff CA, Alexander DC and Clark AE. Clinical use of a bioactive glass particulate in the treatment of human osseous defects. Compend. Contin. Educ. Dent. (1997) 18: 352-354, 356, 358 passim.
(13) Zamet JS, Darbar UR, Griffiths GS, Bulman JS, Brägger U, Bürgin W and Newman HN. Particulate bioglass as a grafting material in the treatment of periodontal intrabony defects. J. Clin. Periodontol. (1997) 24: 410-418.
(14) Lovelace TB, Melloni JT, Meffert RM, Jones AA, Nummikoski PV and Cochran DL. Clinical evaluation of bioactive glass in the treatment of periodontal osseous defects in humans. J. Periodontal. (1998) 69: 1027-1035.
(15) Vallet-Regí M, Ragel CVand Salinas AJ. Glasses for Medical Application. Eur. J. Inorg. Chem. (2003) 6: 1026-1042.
(16) Wheeler DL, Montfort MJ and McLoughlin SW. Differential healing response of bone adjacent to porous implants coated with hydroxyapatite and 45S5 bioactive glass. J. Biomed. Mater. Res. (2001) 55: 603-612.
(17) Chouzouri G and Xanthos M. In vitro bioactivity and degradation of polycaprolactone composites containing silicate fillers. Acta. Biomater. (2007) 3: 745-756.
(18) Sepulveda F, Jones JR and Hench LL. Bioactive sol-gel foams for tissue repair. J. Biomed. Mater. Res. (2002) 59: 340-348.
(19) Rectenwald JE, Minter RM, Rosenberg JJ, Gaines GC, Lee S and Moldawer LL. Bioglass attenuates a proinflammatory response in mouse peritoneal endotoxicosis. Shock. (2002) 17: 135-138.
(20) Stupp SI and Ciegler GW. Organopalettes: materials for artificial bone. I. Synthesis and microstructure. J. Biomed. Mater. Res. (1992) 26: 169-183.
(21) Webster TJ, Ergun C, Doremus RH, Siegel RW and Bizios R. Enhanced osteoclast-like cell functions on nanophase ceramics. Biomaterials. (2001) 22: 1327-1333.
(22) Murugan R, Panduranga Rao K and Sampath Kumar...
TS. Heat-deproteinated xenogeneic bone from slaughterhouse waste: physico-chemical properties. *Bull. Mater. Sci.* (2003) 26: 523–528.

(23) Doostmohammadi A, Monsii A, Salehi R, Fathi MH, Seyedjafari E, Sha fiee A and Soleimani M. Cytotoxicity evaluation of 63S bioactive glass and bone-derived hydroxyapatite particles using human bone-marrow stem cells. *Biomed. Pap. Med. Fac. Univ. Palacky, Olomouc. Czech. Repub.* (2011) 155: 323-326.

(24) Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A and Izzo NJ Jr. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. *Proc. Natl. Acad. Sci. U S A.* (1998) 95: 2979-2984.

(25) Mirian M, Zarghi A, Sadeghi S, Tabarak P, Tavallaee M, Dadrass O and Sadeghi-aliabadi H. Synthesis and cytotoxic evaluation of some novel sulfonamide derivatives against a few human cancer cells. *Iran. J. Pharm. Res.* (2011) 10: 741-748.

(26) Mortazavi V, Nahrkhalaji MM, Fathi MH, Mousavi SB and Esfahani BN. Antibacterial effects of sol-gel-derived bioactive glass nanoparticle on aerobic bacteria. *J. Biomed. Mater. Res. A.* (2010) 94: 160-168.

(27) Oonishi H, Kushitani S, Yasukawa E, Iwaki H, Hench LL, Wilson J, Tsuji E and Sugihara T. Particulate bioglass compared with hydroxyapatite as a bone graft substitute. *Clin. Orthop. Relat. Res.* (1997) 334: 316-325.

(28) Allan I, Newman H and Wilson M. Antibacterial activity of particulate bioglass against supra- and subgingival bacteria. *Biomaterials.* (2001) 22: 1683-1687.

(29) Loppäranta O, Vaahtio M, Peltola T, Zhang D, Hupa L, Hupa M, Ylänen H, Salonen JI, Viljanen MK and Ercola E. Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria *in-vitro.* *J. Mater. Sci. Mater. Med.* (2008) 19: 547-551.

(30) Webster TJ, Siegel RW and Bizios R. Osteoblast adhesion on nanophase ceramics. *Biomaterials.* (1999) 20: 1221-1227.

(31) Webster TJ, Ergun C, Doremus RH, Siegel RW and Bizios R. Enhanced functions of osteoblasts on nanophase ceramics. *Biomaterials.* (2000) 21: 1803-1810.

(32) Waltimo T, Brunner TJ, Vollenweider M, Stark WJ and Zehnder M. Antimicrobial effect of nanometric bioactive glass 45S5. *J. Dent. Res.* (2007) 86: 754-757.

(33) Tavakoli M, Bateni E, Rismanchian M, Fathi M, Doostmohammadi A, Rabiei A Sadeghi H, Etelbari M and Mirian M. Genotoxicity effects of nano bioactive glass and Novabone bioglass on gingival fibroblasts using single cell gel electrophoresis (comet assay): An *in-vitro* study. *Dent. Res. J. (Isfahan)* (2012) 9: 314-320.

This article is available online at http://www.ijpr.ir
Tell us if we are wrong?
Visit http://www.ijpr.ir
or
http://ijpr.sbmui.ac.ir